Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 7/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20168375 | 0.85 | EGFR (0.44) | ALDH1A1KDM4EUSP2EGFRERBB2 | |
| SCHEMBL31395132 | 0.81 | XDH (0.46) | P2RX3P2RX2SRC | |
| SCHEMBL29620984 | 0.78 | MAOB (0.50) | — | |
| SCHEMBL22925872 | 0.78 | MAOB (0.50) | — | |
| SCHEMBL31435335 | 0.78 | KDM4E (0.44) | ALDH1A1KDM4EUSP2EGFRERBB2 | |
| SCHEMBL23976562 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KDM4E | |
| SCHEMBL1404661 | 0.75 | ALDH1A1 (0.42) | ALDH1A1KDM4EUSP2EGFRERBB2 | |
| SCHEMBL25404796 | 0.75 | PIN1 (0.46) | ALDH1A1KDM4E | |
| SCHEMBL31390132 | 0.74 | AXL (0.43) | ALDH1A1P2RX3P2RX2 | |
| SCHEMBL17310145 | 0.74 | AXL (0.43) | ALDH1A1P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | ALDH1A1 4807/4885KDM4E 623/4885USP2 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.